<DOC>
	<DOCNO>NCT02449993</DOCNO>
	<brief_summary>This prospective examination ribonucleic acid ( RNA ) extract tumor material breast cancer patient treat neo-adjuvant therapy . The RNA analyse expression estrogen receptor ( ER 1 ) , progesterone receptor ( PgR ) , HER2 Ki-67 MammaTyper™ . According determined value individual parameter least 4 subtypes distinguish date - Luminal A-type - Luminal B-type - HER2-type - Triple-negative-type As non-clinical endpoint , agreement new subtyping Immunohistochemical method evaluate . As clinical objective , 5 year Distant metastasis free survival ( DMFS ) Overall survival ( OS ) reevaluate accord new subtyping .</brief_summary>
	<brief_title>Re-Examination Tumor Material Re-Evaluation Patient Data From Patients Treated With Neo-adjuvant Therapy</brief_title>
	<detailed_description>Tumor material collect patient receive neoadjuvant therapy either four cycle doxorubicin 60 mg/m² plus pemetrexed 500 mg/m² day 1 every 21 day follow four cycle docetaxel 100 mg/m² day 1 every 21 day four cycle doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² day 1 every 21 day follow four cycle docetaxel 100 mg/m² day 1 every 21 day re-analyzed MammaTyper Kit . The Kit in-vitro molecular diagnostic test molecular subtyping breast cancer Luminal A &amp; B , HER2 Triple negative . It allow quantitative detection RNA expression status gene estrogen receptor ( ESR1 ) , PgR , HER2 Ki-67 basis mRNA present sample . This prospective diagnostic study investigate subtyping-results MammaTyper™ analysis compare subtyping former immunohistochemical analysis perform . Based MammaTyper™-subtypes efficiency therapy regimen outcome re-evaluated patient data .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Women age 1870 year histologically confirm primary invasive breast cancer stage T2T4/N0N2/M0 tumor size ≥ 2 cm measure ultrasound The patient provide write informed consent analysis tumor material Prior anticancer therapy anthracycline prior antitumor therapy breast cancer Inflammatory exulcerating breast cancer A second primary malignancy [ except carcinoma situ ( CIS ) cervix adequately treat nonmelanoma skin cancer ] unless diagnose treat ≥ 5 year ago evidence recurrence Any serious concomitant systemic disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>diagnostic study</keyword>
	<keyword>analysis estrogen receptor</keyword>
	<keyword>progesterone receptor</keyword>
	<keyword>Human epidermal growth factor receptor 2</keyword>
	<keyword>Ki-67</keyword>
</DOC>